Change over period: —
NSE · EXPLEOSOL
EXPLEOSOL
-31.6% from the 52-week high · +18.3% above the low
Expleo Solutions Ltd. engages in the provision of software validation and verification services to the banking and financial services industry. The company is headquartered in Chennai, Tamil Nadu and currently employs 3,931 full-time employees. The company went IPO on 2009-10-26. The firm provides software services, which includes software validation and verification services, software development and engineering consultancy services related to aerospace, automotive, defense and rail industry, and banking, financial services and insurance (BFSI). The firm has capabilities in various fields, such as artificial intelligence (AI) engineering, digitalization, hyper-automation, cybersecurity and data science. The firm has invested in four wholly owned subsidiaries in Singapore, the Unites States of America, the United Kingdom and the United Arab Emirates for market development and service delivery in the respective regions. Its subsidiaries include Expleo Solutions Pte. Ltd., Expleo Solutions UK Ltd., Expleo Solutions Inc. and Expleo Solutions FZE.
The short version. EXPLEOSOL reported revenue of ₹293 crore for Sep 2026, up 3.5% from a year earlier. Net profit was ₹36 crore (down 10.0% year on year). Return on equity was 16.0% in Mar 2026. Promoter holding was 71.05% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
EXPLEOSOL trades 31.6% below its 52-week high and 18.3% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹293 cr.
Sep 2026 net profit of ₹36 cr.
1.7 pts lower than a year earlier.
Revenue compounded at 7.6% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 293 | 292 | 286 | 279 | 283 | 260 | 256 | 258 |
| Net profit | 36 | 34 | 42 | 22 | 40 | 20 | 24 | 20 |
| Net margin % | 12.4 | 11.7 | 14.6 | 7.9 | 14.1 | 7.9 | 9.4 | 7.7 |
| EPS (₹) | 23.45 | 22.02 | 26.85 | 14.26 | 25.62 | 13.16 | 15.51 | 12.75 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1108 | 1025 | 965 | 903 | 405 | 301 | 269 | 283 |
| Net profit | 124 | 103 | 90 | 134 | 54 | 50 | 40 | 36 |
| Net margin % | 11.2 | 10.1 | 9.4 | 14.8 | 13.3 | 16.8 | 14.8 | 12.8 |
| EPS (₹) | 79.89 | 66.52 | 58.27 | 130.59 | 52.58 | 49.2 | 38.92 | 33.79 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 16.0% in Mar 2026; debt to equity is 0.00.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 16.0 | 16.2 | 14.8 | 25.2 |
| Return on capital % | 20.6 | 20.8 | 18.5 | 33.5 |
| EBITDA margin % | 16.9 | 17.5 | 16.0 | 23.5 |
| Net margin % | 10.8 | 9.9 | 9.3 | 14.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 7.6% | 30.2% |
| Profit CAGR | -2.5% | 19.7% |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Down 0.33 pts over 8 quarters.
Down 0.61 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 71.05 | 71.05 | 71.05 | 71.05 | 71.05 | 71.05 | 71.05 | 71.05 | 0.0 |
| FII | 0.49 | 0.33 | 0.1 | 0.13 | 0.32 | 0.42 | 0.13 | 0.16 | -0.33 |
| DII | 1.0 | 0.91 | 0.84 | 0.84 | 0.07 | 0.01 | 0.12 | 0.39 | -0.61 |
| Public | 27.46 | 27.72 | 28.02 | 27.99 | 28.56 | 28.53 | 28.7 | 28.4 | +0.94 |
Mutual fund holdings · Oct 2026
1 scheme hold this stock
1 the month before.
- Mirae Asset BSE Information Technology Index Fund0.03% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for EXPLEOSOL are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other IT - Services stocks
Quick answers
Common questions about EXPLEOSOL
What is the EXPLEOSOL share price?
EXPLEOSOL (EXPLEOSOL) last closed at ₹772.95, up 1.04% on the day. Its 52-week range is ₹646.90 to ₹1,118.50.
What is the market cap of EXPLEOSOL?
EXPLEOSOL has a market capitalisation of about ₹1,187 crore. Its price-to-earnings ratio is 8.5.
How are EXPLEOSOL's latest results?
EXPLEOSOL reported revenue of ₹293 crore for Sep 2026, up 3.5% from a year earlier. Net profit was ₹36 crore (down 10.0% year on year). Return on equity was 16.0% in Mar 2026. Promoter holding was 71.05% in Sep 2026, up 0.00 points over 8 quarters.
Who owns EXPLEOSOL?
As of Sep 2026, shareholding was: Promoter 71.05%, FII 0.16%, DII 0.39%, Public 28.4%.
How many mutual funds hold EXPLEOSOL?
1 mutual fund schemes held EXPLEOSOL in October 2026. That compares with 1 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 12 Feb 2025 · Interim Dividend - Rs. 50
- 14 Jul 2023 · Dividend - Rs. 5
- 19 Jul 2018 · Final Dividend - Rs. 20
- 09 Nov 2017 · Interim Dividend - Rs. 4
- 20 Jul 2017 · Final Dividend - Rs. 20
- 03 Nov 2016 · Interim Dividend - Rs. 4
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.